3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Hepatocellular
36
Carcinoma, Non-Small-Cell Lung
17
Small Cell Lung Carcinoma
16
Neoplasms
14
Lung Neoplasms
13
Breast Neoplasms
7
Melanoma
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Liver Neoplasms
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Glioblastoma
4
Endometrial Neoplasms
4
Sarcoma
3
Recurrence
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Carcinoma, Transitional Cell
3
Carcinoma, Squamous Cell
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Small Cell Lung Cancer Extensive Stage
2
Sarcoma, Alveolar Soft Part
2
Ovarian Neoplasms
2
Osteosarcoma
2
Mesothelioma, Malignant
2
Interventions
Etoposide
3
Carboplatin
3
atezolizumab
2
tislelizumab
1
pembrolizumab
1
irinotecan sucrosofate
1
apatinib
1
Radiotherapy
1
Platinum
1
NPI 2358
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Small Cell Lung Cancer Extensive Stage
×
atezolizumab
×
Clear all
NCT07227597
2026-05-26
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled
NCT05703971
2025-10-16
Acclaim-3
Genprex, Inc.
Phase 1/2
Recruiting
62 enrolled